CCXI - ChemoCentryx, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue82,49711,935-
Cost of Revenue---
Gross Profit82,49711,935-
Operating Expenses
Research Development49,49537,94533,183
Selling General and Administrative16,50914,71014,506
Non Recurring---
Total Operating Expenses---
Operating Income or Loss16,493-40,720-47,689
Income from Continuing Operations
Total Other Income/Expenses Net1,370757384
Earnings Before Interest and Taxes17,863-39,963-47,305
Interest Expense444
Income Before Tax17,859-39,963-47,305
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops17,859-39,963-47,305
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income17,859-39,963-47,305
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares17,859-39,963-47,305